Suppr超能文献

相似文献

1
Mechanisms of tau-induced neurodegeneration.
Acta Neuropathol. 2009 Jul;118(1):53-69. doi: 10.1007/s00401-009-0486-3. Epub 2009 Jan 30.
2
Alzheimer neurofibrillary degeneration: significance, etiopathogenesis, therapeutics and prevention.
J Cell Mol Med. 2008 Jan-Feb;12(1):38-55. doi: 10.1111/j.1582-4934.2008.00225.x. Epub 2007 Jan 9.
3
Mechanisms of neurofibrillary degeneration and the formation of neurofibrillary tangles.
J Neural Transm Suppl. 1998;53:169-80. doi: 10.1007/978-3-7091-6467-9_15.
4
Tau pathology in Alzheimer disease and other tauopathies.
Biochim Biophys Acta. 2005 Jan 3;1739(2-3):198-210. doi: 10.1016/j.bbadis.2004.09.008.
5
Mechanism of neurofibrillary degeneration and pharmacologic therapeutic approach.
J Neural Transm Suppl. 2000;59:213-22. doi: 10.1007/978-3-7091-6781-6_22.
7
Tau in Alzheimer disease and related tauopathies.
Curr Alzheimer Res. 2010 Dec;7(8):656-64. doi: 10.2174/156720510793611592.
8
Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration.
Eur J Neurosci. 2007 Jan;25(1):59-68. doi: 10.1111/j.1460-9568.2006.05226.x.
9
Alzheimer neurofibrillary degeneration: therapeutic targets and high-throughput assays.
J Mol Neurosci. 2003;20(3):425-9. doi: 10.1385/jmn:20:3:425.
10
AMPK is abnormally activated in tangle- and pre-tangle-bearing neurons in Alzheimer's disease and other tauopathies.
Acta Neuropathol. 2011 Mar;121(3):337-49. doi: 10.1007/s00401-010-0759-x. Epub 2010 Oct 19.

引用本文的文献

1
The Role and Pathogenesis of Tau Protein in Alzheimer's Disease.
Biomolecules. 2025 Jun 5;15(6):824. doi: 10.3390/biom15060824.
2
Bioactive compound nanoparticles for Alzheimer's disease.
Inflammopharmacology. 2025 Jun 5. doi: 10.1007/s10787-025-01801-2.
5
Neuroprotective Potential of the Flavonoids Quercetin and Epicatechin in a C. elegans Tauopathy Model.
Mol Nutr Food Res. 2025 Aug;69(15):e70108. doi: 10.1002/mnfr.70108. Epub 2025 May 12.
8
9
Immune Modulation in Alzheimer's Disease: From Pathogenesis to Immunotherapy.
Cells. 2025 Feb 12;14(4):264. doi: 10.3390/cells14040264.
10
Identification of a novel pyrrolo[2,3-]pyridine compound as a potent glycogen synthase kinase 3β inhibitor for treating Alzheimer's disease.
J Enzyme Inhib Med Chem. 2025 Dec;40(1):2466846. doi: 10.1080/14756366.2025.2466846. Epub 2025 Feb 20.

本文引用的文献

1
Anesthesia induces phosphorylation of tau.
J Alzheimers Dis. 2009;16(3):619-26. doi: 10.3233/JAD-2009-1003.
2
Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities.
Nat Rev Drug Discov. 2008 Dec;7(12):1013-30. doi: 10.1038/nrd2755.
3
White matter tauopathy with globular glial inclusions: a distinct sporadic frontotemporal lobar degeneration.
J Neuropathol Exp Neurol. 2008 Oct;67(10):963-75. doi: 10.1097/NEN.0b013e318187a80f.
4
Increased dosage of Dyrk1A alters alternative splicing factor (ASF)-regulated alternative splicing of tau in Down syndrome.
J Biol Chem. 2008 Oct 17;283(42):28660-9. doi: 10.1074/jbc.M802645200. Epub 2008 Jul 24.
6
A potent mechanism-inspired O-GlcNAcase inhibitor that blocks phosphorylation of tau in vivo.
Nat Chem Biol. 2008 Aug;4(8):483-90. doi: 10.1038/nchembio.96. Epub 2008 Jun 29.
7
Overexpression of Dyrk1A contributes to neurofibrillary degeneration in Down syndrome.
FASEB J. 2008 Sep;22(9):3224-33. doi: 10.1096/fj.07-104539. Epub 2008 May 28.
9
Proteasome inhibition increases tau accumulation independent of phosphorylation.
Neurobiol Aging. 2009 Dec;30(12):1949-61. doi: 10.1016/j.neurobiolaging.2008.02.012. Epub 2008 Apr 10.
10
Akt and CHIP coregulate tau degradation through coordinated interactions.
Proc Natl Acad Sci U S A. 2008 Mar 4;105(9):3622-7. doi: 10.1073/pnas.0709180105. Epub 2008 Feb 21.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验